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We have previously demonstrated that quercetin, a bioﬂavonoid, blocks hepatitis C virus (HCV)
proliferation by inhibiting NS5A-driven internal ribosomal entry site (IRES)-mediated translation of the
viral genome. Here, we investigate the mechanisms of antiviral activity of quercetin and six additional
bioﬂavonoids. We demonstrate that catechin, naringenin, and quercetin possess signiﬁcant antiviral
activity, with no associated cytotoxicity. Infectious virion secretion was not signiﬁcantly altered by
these bioﬂavonoids. Catechin and naringenin demonstrated stronger inhibition of infectious virion
assembly compared to quercetin. Quercetin markedly blocked viral translation whereas catechin and
naringenin demonstrated mild activity. Similarly quercetin completely blocked NS5A-augmented IRES-
mediated translation in an IRES reporter assay, whereas catechin and naringenin had only a mild effect.
Moreover, quercetin differentially inhibited HSP70 induction compared to catechin and naringenin.
Thus, the antiviral activity of these bioﬂavonoids is mediated through different mechanisms. Therefore
combination of these bioﬂavonoids may act synergistically against HCV.
& 2012 Elsevier Inc. All rights reserved.Introduction
The hepatitis C virus (HCV) infects 3% of the world population
and is mainly responsible for liver transplantation in patientsll rights reserved.
cellular carcinoma; PEG-IFN,
sponse; NCR, noncoding
uctural; NS5A, nonstructural
rescent protein; RLuc, Renilla
methyl sulfoxide; HCVcc,
eﬂy luciferase
IH AI084090, AD; California
y of California Ofﬁce of the
Laboratory Medicine, UCLA
Los Angeles, CA 90095-1732,
rian),
mi),
du (G.K. Yeh),
la.edu (J. Wang),
ucla.edu (S.W. French).with cirrhosis in developed countries (Shepard et al., 2005).
Furthermore, HCV is the most common chronic blood borne
pathogen in the United States (US) affecting 1.8% of the popula-
tion and is the major etiologic factor responsible for the recent
doubling of hepatocellular carcinoma (HCC) (El-Serag, 2002).
HCV infection is currently treated by pegylated interferon-a
(PEG-IFN) and ribavirin with a sustained virologic response (SVR)
of only 50–56% in patients with genotype 1 (Gambarin-Gelwan
and Jacobson, 2008). Adverse side effects and contraindications
are common for therapy of all genotypes as well (McHutchison
and Patel, 2002). Recently, NS3/4A protease inhibitors in combi-
nation with PEG-IFN and ribavirin led to an increased SVR, but
also increased adverse events including anemia and gastrointest-
inal symptoms (Ciesek and Manns, 2011). Nevertheless, a sig-
niﬁcant number of patients cannot receive these treatments as
they require PEG-IFN. For these reasons, there is the need to
develop adjunct or replacement therapies that are less toxic and
more efﬁcacious in terms of higher SVR rates and HCC prevention.
The 50 non-coding region (NCR) of the viral genome possesses an
internal ribosomal entry site (IRES) (Wang et al., 1993), a cis-acting
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that allows ribosomal translation initiation to occur internally within
a transcript in lieu of 50-cap dependent translation (Pacheco
and Martinez-Salas, 2010). The HCV viral life cycle in a cell can be
divided into six phases: (1) binding and internalization, (2) cytoplas-
mic release and uncoating, (3) viral polyprotein translation
and processing, (4) RNA genome replication, (5) packaging and
assembly, and (6) virus morphogenesis and secretion (Moradpour
et al., 2007).
The viral nonstructural protein 5A (NS5A), a 56–59 kDa phos-
phoprotein, is a multi-functional protein and a component of the
viral replicase complex. It has been implicated in regulation of
HCV genome replication, viral protein translation, virion assem-
bly, and viral secretion (He et al., 2003; Hughes et al., 2009;
Tellinghuisen et al., 2008). We have previously identiﬁed, through
co-immunoprecipitation, an NS5A/HSP complex composed of
NS5A, HSP70, and HSP40 (cofactor of HSP70) and demonstrated
their colocalization in Huh-7 cells (Gonzalez et al., 2009). We
further showed that both NS5A-augmented IRES-mediated trans-
lation and virus production are blocked by (1) HSP70 knockdown,
(2) the HSP synthesis inhibitor quercetin, a bioﬂavonoid, and (3) a
small peptide from NS5A domain I that is capable of blocking
NS5A/HSP70 interaction, with no associated cytotoxicity
(Gonzalez et al., 2009; Khachatoorian et al., 2012). These ﬁndingsFig. 1. Molecular structure of the bioﬂavonoids. Bioﬂavonoid molecular structures
are adapted from Sigma-Aldrich. For naringenin, the structure of the
(S) enantiomer is shown; however, the chemical is a racemic mixture of both
enantiomers. Silibinin is the major active component of silymarin.support our hypothesis that HCV utilizes an NS5A/HSP complex to
facilitate IRES-mediated translation of its genome and that
disruption of this complex by quercetin-mediated knockdown of
HSP70 blocks viral proliferation, implicating quercetin as a
potential HCV treatment option.
Bioﬂavonoids are a group of plant secondary metabolites that
serve a variety of functions in plants including pigmentation and
resistance to predators. The basic structure of bioﬂavonoids
consists of two phenyl moieties linked together by three carbons
(Fig. 1A). A variety of functional groups occur at different posi-
tions on this backbone to give rise to the large selection of these
naturally occurring compounds. In recent years, bioﬂavonoids
have been extensively studied for their health beneﬁts.
In this study, we sought to examine, in more detail, the effect
of quercetin and a number of bioﬂavonoids structurally related to
quercetin on viral proliferation and to obtain further insights into
the mechanisms of bioﬂavonoid-mediated suppression of HCV
production.Results
We have previously shown that quercetin blocks virus produc-
tion with no associated cytotoxicity (Gonzalez et al., 2009). Here,
we sought to determine if a number of other bioﬂavonoids
structurally related to quercetin would also possess antiviral
activity. We tested a total of seven compounds from a variety of
bioﬂavonoid groups: catechin and epicatechin (ﬂavanols), genis-
tein (an isoﬂavone), luteolin (a ﬂavone), naringenin (a ﬂavanone),
quercetin (a ﬂavonol), and silymarin (a mixture of ﬂavonolignans,
where silibinin is the major active component (Wellington and
Jarvis, 2001)) (Fig. 1).
Screening of bioﬂavonoids for cellular toxicity
We ﬁrst determined the cellular toxicity of these seven
compounds at a concentration range of 25 and 125 mM using
standard MTT assays. As shown in Fig. 2A, the bioﬂavonoids can
be divided into three groups based on their cytotoxicity proﬁles.
Genistein and luteolin, potential chemotherapeutic agents, dis-
play signiﬁcant cytotoxicity and were not studied further. Nar-
ingenin, quercetin, and silymarin possess a cytotoxicity proﬁle
similar to DMSO carrier. Interestingly, catechin and epicatechin
result in signiﬁcantly increased absorbance. This may reﬂect an
increase in metabolism, cell division, or cell size; decreased
apoptosis; or increased mitochondrial biogenesis. This is a subject
of ongoing study. In a separate experiment, we analyzed the
toxicity of all bioﬂavonoids in a time course of 72 h, and we
obtained a similar toxicity proﬁle (Fig. 2B).
Catechin, quercetin, and naringenin signiﬁcantly attenuate HCV
production in a dose-dependent manner
Next, we tested the bioﬂavonoids for their antiviral activity
using the HCV cell culture (HCVcc) system measuring intracel-
lular levels of HCV-driven protein expression. Based on our
preliminary analyses, we found the concentration range of
25–125 mM bioﬂavonoids to be the most informative for the
assays conducted in this study in terms of distinguishing bio-
ﬂavonoid effects on the stages of viral life cycle. Initially, huh-7.5
cells were infected with the reporter virus and treated with
25 mM bioﬂavonoid for 48 h, followed by measuring luciferase
activity. Quercetin and naringenin displayed signiﬁcant antiviral
activity in agreement with previous reports (Goldwasser et al.,
2011; Gonzalez et al., 2009) (Fig. 3A). In addition, we found
catechin to possess signiﬁcant antiviral activity as well (Fig. 3A).
Fig. 2. Cytotoxicity of bioﬂavonoids as determined by MTT assays. (A) Bioﬂavonoid cellular toxicity proﬁle in a concentration range of 25–125 mM. MTT assays were
performed 72 h post treatment. (B) Bioﬂavonoid cellular toxicity proﬁle in a time course of 72 h at 125 mM. All data was normalized to time 0. Boxes indicate ﬂavonoids
grouped together based on similar toxicity proﬁles. (Error bars reﬂect standard deviation.)
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played a slight increase in virus production (Fig. 3A). We are
currently investigating the opposite effects of catechin and
epicatechin on viral proliferation levels. The observed antiviral
activities were not indirect effects of bioﬂavonoids on luciferase
expression as determined independently by transfection of a
plasmid expressing Renilla luciferase (Fig. 3B). Silymarin did not
result in viral attenuation at 25 mM dose (Fig. 3A). None of the
compounds displayed any cytotoxicity in MTT assays (Fig. 3C).
We speculated that higher concentrations of silymarin may dis-
play some antiviral activity as reported previously (Wagoner
et al., 2010). As shown in Fig. 3D, 125 mM silymarin resulted in
a modest antiviral activity in a 48 h assay. However, silymarin
was not studied further due to its signiﬁcantly lower antiviral
activity compared with the other bioﬂavonoids.
Intracellular viral levels were also determined with a treat-
ment range of 25–125 mM catechin, naringenin, and quercetin for
72 h. All three compounds displayed a dose-dependent antiviral
activity with quercetin being the most potent bioﬂavonoid
followed by catechin and naringenin (Fig. 4A). To further conﬁrm
the antiviral activity of these compounds, the supernatants of
these cultures were concentrated 30-fold to remove approxi-
mately 97% of bioﬂavonoids, and the concentrated supernatants
were used to infect naı¨ve cells. As shown in Fig. 4B, infectious
virus production was signiﬁcantly decreased in a dose-dependent
manner.
To further conﬁrm the antiviral activity of catechin, narin-
genin, and quercetin, huh-7.5 cells were infected and treated with
catechin, naringenin, and quercetin for 72 h as above, followed by
measuring viral RNA levels by quantitative reverse transcriptase
PCR as well as assaying NS5A protein levels by Western analysis.As shown in Fig. 4C and D, all three compounds signiﬁcantly
reduced viral RNA and NS5A protein levels, in agreement with the
luciferase reporter levels.Quercetin markedly inhibits intracellular viral protein production
compared to catechin and naringenin
We proceeded to determine the mechanism(s) of action of
catechin, quercetin, and naringenin, using the HCVcc system. To
test the bioﬂavonoid inhibition of viral protein production, huh-
7.5 cells were infected and immediately treated with 125 mM of
bioﬂavonoid. 125 mM concentration was chosen as it was optimal
for distinguishing the mechanism of antiviral activity of the
bioﬂavonoids. Luciferase assays 20 h after treatment showed that
catechin, quercetin, and naringenin signiﬁcantly inhibited intra-
cellular viral protein translation, with quercetin demonstrating
more than two-fold higher activity than catechin and naringenin
(Fig. 5A). The 20-h assay time is crucial to limit the assay to one
viral life cycle (see below) and eliminate any possible effects of
bioﬂavonoids on other stages of viral life cycle such as virion
assembly and secretion.
We also monitored translation levels within 28 h after infec-
tion. As shown in Fig. 5B, with no bioﬂavonoid treatment, viral
translation levels steadily increased followed by sharp burst in
viral translation between 24 and 28 h time points. This was
interpreted to result from secondary infection. From this we
inferred that the viral cycle duration is between 20 and 24 h.
Bioﬂavonoid treatment signiﬁcantly decreased viral protein pro-
duction during one viral life cycle and afterwards (Fig. 5B). Quite
interestingly, quercetin, our most potent bioﬂavonoid, inhibits
Fig. 3. Bioﬂavonoid antiviral activity. (A) Effect of 25 mM bioﬂavonoids on viral proliferation. Huh-7.5 cells were infected with the reporter virus and immediately treated
with bioﬂavonoids. Forty-eight hours post treatment, luciferase activity was assayed. (B) Effect of bioﬂavonoids on Renilla activity. Luciferase assays were performed on
cells transfected with pRL-TK plasmid. (C) MTT assays performed in parallel with assays in parts (A) and (B). (D) Effect of 125 mM silymarin on viral proliferation. Huh-7.5
cells were infected with the reporter virus and treated with bioﬂavonoids for 48 h as in part (A), followed by luciferase assay. (n, nn, and nnn indicate Po0.05, Po0.005, and
Po0.0005, respectively. Error bars reﬂect standard deviation.)
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cycle (Fig. 5B).
Infectious virion secretion is not inhibited by catechin, naringenin,
and quercetin
To determine the effect of bioﬂavonoids on infectious virion
secretion, huh-7.5 cells were infected with the reporter virus.
After 24 h, allowing for sufﬁcient accumulation of intracellular
virus, cells were washed to remove secreted virions and treated
with 125 mM bioﬂavonoid for 5 h. This limited time of treatment
is necessary to minimize their effect on viral protein production.
Subsequently, supernatants were concentrated 30-fold to remove
approximately 97% of bioﬂavonoids. Elimination of bioﬂavonoids
is necessary to exclude their potential subsequent effects on
infection of naı¨ve cells. The concentrated supernatants were used
to infect naı¨ve cells. While catechin and quercetin slightly
affected viral secretion compared with DMSO, the differences
were not statistically signiﬁcant and may reﬂect their potent
translation inhibitory effects during the 5 h infection period
(Fig. 6A). As a positive control, treatment with Brefeldin A (BFA),
an inhibitor of Golgi-dependent secretion including viral secre-
tion (Goldwasser et al., 2011), did signiﬁcantly reduce viral
secretion (Fig. 6A).We also ensured that concentrating the culture supernatants
indeed removes the bioﬂavonoids. Aliquots of culture medium
were prepared containing 125 mM of catechin, naringenin, or
quercetin. Two sets of huh-7.5 cells were infected. After the
infection period, the supernatants of one set of cells were
replaced by the media containing the bioﬂavonoids as done for
all assays in this study. However, for the second set of cells, the
medium was subjected to ﬁltration in the same manner as above,
and the cleared medium was used to replace the culture super-
natants. Luciferase activity was assayed for both sets 48 h after
infection. The ﬁltration step abolished the antiviral activity that
was observed with no ﬁltration (Fig. 6B).
Catechin, naringenin, and quercetin signiﬁcantly inhibit intracellular
infectious virion assembly
We next determined the effect of bioﬂavonoids on viral
assembly. Two sets of huh-7.5 cells were infected and treated
with BFA. One set was used for the assembly assay and the
‘control set’ for measuring viral translation (below). BFA treat-
ment was performed to trap all assembled virions in the cyto-
plasm of infected cells. This step is necessary to limit the effect of
bioﬂavonoid treatment to viral assembly alone, as opposed to
viral secretion. Three hours later, cells were treated with 125 mM
Fig. 4. Dose dependent antiviral activity of catechin, naringenin, and quercetin. (A) Huh-7.5 cells were infected with the Renilla reporter virus and immediately treated
with a concentration range of 25–125 mM of each bioﬂavonoid for 72 h, followed by measuring luciferase activity. (B) Luciferase assays performed on cells infected with
the concentrated supernatants of the cells in Fig. 4A. Huh-7.5 cells were infected with supernatants and harvested 72 h later. (C) Bioﬂavonoid effect on viral genome levels.
Huh-7.5 cells were infected with the reporter virus and treated with 125 mM bioﬂavonoid for 72 h followed by quantitative reverse-transcriptase PCR. (D) Bioﬂavonoid
effect on viral protein levels. Western analyses for NS5A and loading control tubulin were performed on the same samples from part (C). (n and nn indicate Po0.05 and
Po0.005, respectively. Error bars reﬂect standard deviation.)
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is necessary to minimize the effect of bioﬂavonoids on viral
protein translation. Supernatants were removed and saved to
determine infectious virion production (see below). After adding
fresh medium, cells were subjected to three cycles of freeze/thaw
to release intracellular virions. The medium was cleared of
cellular debris and used to infect naı¨ve cells. As shown in
Fig. 7A, all three bioﬂavonoids signiﬁcantly blocked infectiousvirion assembly; here catechin and naringenin demonstrated
more potency compared to quercetin.
Luciferase assays of the ‘control set’ of cells showed no
signiﬁcant decrease in viral translation (Fig. 7B). BFA inhibition
of secretion was veriﬁed by infection of naı¨ve cells with the
supernatants of the original infection. As shown in Fig. 7C, BFA
treatment abolished viral secretion as expected, while signiﬁcant
viral secretion occurred when cells were treated with DMSO.
Fig. 5. Bioﬂavonoid effect on intracellular viral protein production. (A) Huh-7.5
cells were infected with the reporter virus and immediately treated with 125 mM
bioﬂavonoid. Twenty hours later, luciferase levels were measured. (B) Luciferase
assays performed in a similar way, but at different time points after infection. All
values were normalized to the 24 h time point. (nn and y indicate Po0.005 and
Po0.000005, respectively. Error bars reﬂect standard deviation.)
Fig. 6. Bioﬂavonoid effect on infectious virion secretion. (A) Huh-7.5 cells were
infected and 24 h later, treated with 125 mM bioﬂavonoid for 5 h. Supernatants
were immediately removed and concentrated 30-fold to remove approx. 97% of
the bioﬂavonoids and used to infect naı¨ve cells, followed by luciferase assays 72 h
later. (B) Control experiment to determine if concentration effectively removed
bioﬂavonoids from supernatants in part (A). Two sets of huh-7.5 cells were
infected with the reporter virus. Subsequently, the supernatants of one set of
cells were replaced with medium containing 125 mM bioﬂavonoid. For the other
set of cells, the media containing 125 mM bioﬂavonoid were ﬁltered and concen-
trated to remove the bioﬂavonoids. The cleared medium was then used to replace
the culture supernatants. Seventy-two hours later, luciferase activity was mea-
sured. (nnnn and y indicate Po0.00005 and Po0.000005, respectively. Error bars
reﬂect standard deviation.)
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whereas naringenin and catechin exhibit mild activity
We tested catechin, naringenin, and quercetin in a previously
described cell culture-based bicistronic reporter system to mea-
sure levels of viral internal ribosomal entry site (IRES)-mediated
translation (Gonzalez et al., 2009). This reporter consists of a
Renilla luciferase (RLuc) open reading frame (ORF) and a Fireﬂy
luciferase (FLuc) ORF driven by a 50-cap and HCV IRES, respec-
tively (Fig. 8A). The ratio of Fireﬂy to Renilla luciferase values
(FLuc/RLuc) reﬂects the levels of HCV IRES-mediated translation.
We have previously shown that quercetin suppresses the NS5A-
driven increase in IRES-mediated translation (Gonzalez et al.,
2009). In this study, 293T cells were transfected with the reporter
construct and either NS5A or GFP (control) and treated with
125 mM bioﬂavonoid for 72 h after which, cells were assayed for
dual luciferase activity. All bioﬂavonoids signiﬁcantly decreased
IRES-mediated translation compared with DMSO (Fig. 8B). Quer-
cetin completely blocked NS5A-augmented IRES activity in
contrast to catechin and naringenin which demonstrated mild
inhibition.Quercetin strongly inhibits heat shock induced HSP70 expression
compared to catechin, naringenin
Quercetin has been reported to inhibit HSP70 expression
through different mechanisms (Elia and Santoro, 1994;
Jakubowicz-Gil et al., 2005). Previously, we have shown HSP70
to form a complex with viral NS5A in vivo (Gonzalez et al., 2009).
Further we recently showed that the NS5A/HSP70 complex is
important for viral protein production in vivo and that disruption
of this complex through a small peptide inhibitor results in a
marked decrease in viral protein synthesis (Khachatoorian et al.,
2012). Based on these observations, we hypothesized that the
translation inhibitory effect of quercetin, as well as catechin and
naringenin, may be mediated by inhibition of HSP70 expression.
To test this hypothesis, huh-7.5 cells were treated with catechin,
naringenin, quercetin, or DMSO (control) for 2 h and subjected to
heat shock at 42 1C for 30 min and allowed to recover at 37 1C for
6 h. Western analysis of cellular lysates with antibody against
HSP70 (speciﬁcally the HSPA1A isoform reported in our previous
studies (Gonzalez et al., 2009; Khachatoorian et al., 2012))
Fig. 7. Bioﬂavonoid effects on assembly. (A) Huh-7.5 cells were infected and immediately treated with 0.1 mg/ml of Brefeldin A (BFA). Thirty-one hours later, cells were
treated with 125 mM bioﬂavonoid for 5 h after which, the medium was removed and saved for further analysis, and cells were washed twice with PBS to remove
bioﬂavonoids. Fresh medium was added, and cells were subjected to three cycles of freeze/thaw. After clearing cellular debris, supernatants were used to infect naı¨ve cells
followed by luciferase assays 72 h later. All values were normalized to ‘DMSOþBFA’. (B) Control experiment to determine if bioﬂavonoids effect viral protein translation in
the conditions of part (A). Huh-7.5 cells were infected and treated with BFA and bioﬂavonoids exactly as described in part (A). Immediately after the 5-h bioﬂavonoid
treatment, cells were washed and lysed, and Renilla luciferase assay was performed. (C) Control experiment to determine the effect of BFA on viral secretion in the original
part (A) assembly assay. The supernatants saved from the original culture were concentrated 30-fold to remove bioﬂavonoids and used to infect naı¨ve cells, followed by
luciferase assays 72 h later. All values were normalized to DMSO treatment. (n, nn, and nnn indicate Po0.05, Po0.005, and Po0.0005, respectively. Error bars reﬂect
standard deviation.)
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tin treated cells (Fig. 8C and D). A slight decrease in HSP70 was
seen for naringenin and catechin treatments (Fig. 8C and D)
consistent with our IRES assay and viral protein production
results above (Figs. 8B and 5, respectively).Discussion
We have previously reported quercetin to efﬁciently block the
NS5A-driven increase in IRES-mediated translation and HCV
production (Gonzalez et al., 2009). In this study, we further
analyzed the mechanisms of action of quercetin and a number
of other bioﬂavonoids structurally related to quercetin.
Initially we tested seven bioﬂavonoids, including quercetin,
for their cellular toxicity, and we found that genistein andluteolin were highly cytotoxic to huh-7.5 cells. Quercetin, nar-
ingenin, and silymarin displayed similar toxicity to the DMSO
carrier, while catechin and epicatechin had the lowest toxicity
and led to a signiﬁcantly increased absorbance in MTT assays.
We conclude that genistein and luteolin are not suitable as anti-
HCV treatments due to their signiﬁcant cytotoxicity at these
concentrations.
Next, we screened the remaining ﬁve bioﬂavonoids for their
antiviral activity. Catechin, naringenin, and quercetin signiﬁcantly
blocked virus production, while silymarin did not have any effect.
Silymarin has previously been shown to inhibit HCV infection in
tissue culture primarily through blocking viral entry (Wagoner
et al., 2010). We did not see this effect. One possible reason is that
we added the compounds after the 3-h infection time, which
would signiﬁcantly reduce the effect of an entry blocker. Further,
the concentration we used was fairly low (25 mM). Others have
Fig. 8. Bioﬂavonoid effects on IRES-mediated translation. (A) Schematic of the bicistronic reporter construct used to measure IRES-mediated translation. Renilla luciferase
(RLuc) and Fireﬂy luciferase (FLuc) are driven by a 50 cap and the HCV IRES, respectively. Fireﬂy to Renilla ratios reﬂect changes in IRES-mediated translation.
(B) Bioﬂavonoid effects on IRES-mediated translation. 293T cells were transfected with the IRES reporter construct and either NS5A or GFP. Twelve hours later, cells were
treated with 125 mM bioﬂavonoid, followed by luciferase assays 72 h later. (C) Western analysis of the effect of bioﬂavonoids on HSP70 levels after heat shock. Huh-7.5
cells were treated with 125 mM bioﬂavonoids for 2 h and subjected to heat shock at 42 1C for 30 min. After 6 h of recovery at 37 1C, cells were lysed, and Western analysis
was performed with antibody against HSP70 (HSPA1A). (D) Densitometry of the Western blot in panel (C). HSP70 quantities were normalized to tubulin. (n, nn, and nnn
indicate Po0.05, Po0.005, and Po0.0005, respectively. Error bars reﬂect standard deviation.)
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infection (the same backbone as used in this study) when treating
at 80 mM (Wagoner et al., 2010).
Epicatechin, a diastereoisomer of catechin, led to increased virus
production compared with DMSO, and is, therefore, not suitable as an
antiviral agent. Recently it was shown that a dimer of catechin and
epicatechin can block HCV pseudotype proliferation (Li et al., 2010).
Our ﬁnding that catechin and epicatechin have opposite effects on
cellular viral levels implies that catechin may be the element in this
dimer that displayed antiviral effects. We are currently investigating
the opposite effects of catechin and epicatechin on virus production
as well as their shared increased absorbance seen in MTT assays. As
shown in Fig. 1, the di-hydro-benzopyran backbone of catechin and
epicatechin possesses a di-hydroxyphenyl and a hydroxyl group on
the pyran moiety. These two groups are oriented differently in three
dimensional space; in catechin they are located on the same side of
the backbone, while in epicatechin they point in opposite directions.
We speculate that the orientation of these side chains may be
responsible for the opposite effects of catechin and epicatechin on
viral protein translation and are currently investigating this possibi-
lity. We have shown previously that viral protein translation is
mediated in part by a complex of NS5A and HSP70 (Gonzalez et al.,
2009; Khachatoorian et al., 2012). Considering our ﬁnding that
catechin can effect HSP70 expression, it may be possible that the
orientation of these side chains determines the effect of catechin and
epicatechin on HSP70 expression potentially through their differential
interactions with the HSP70 transcription factor.
We chose catechin, naringenin, and quercetin for further analysis
because of their antiviral activity. All three bioﬂavonoids signiﬁcantly
block cellular viral levels in the HCVcc system. Quercetin displays a
far more potent effect than catechin and naringenin. Catechin inhibits
viral translation more than naringenin, and we speculate that this
results in the better long-term viral attenuation by catechin com-
pared with naringenin (Fig. 4). We also used the HCV IRES bicistronic
reporter assay system to show that the translation inhibitory effect of
these ﬂavonoids is NS5A dependent as there was no change in IRES-
mediated translation when GFP was used (instead of NS5A) as a
control. This result is consistent with our previous ﬁndings on themechanism of NS5A/HSP70 complex-driven IRES-mediated transla-
tion of viral proteins (Gonzalez et al., 2009; Khachatoorian et al.,
2012).
Intracellular infectious virion assembly is also signiﬁcantly
blocked by catechin and naringenin and to a lesser extent by
quercetin. Naringenin has also been previously reported to block
virion assembly using a different assay (Goldwasser et al., 2011).
Infectious virion secretion is not signiﬁcantly affected by catechin,
naringenin (in agreement with a previous report (Goldwasser
et al., 2011)) and quercetin.
Furthermore, we have shown that catechin, naringenin, and
quercetin effect induction of HSP70 in cells that are subjected to
heat shock. In particular, quercetin has a far stronger inhibitory
effect on HSP70 expression. These results support our hypothesis
that bioﬂavonoids mediate their antiviral effects at least in part
by blocking heat shock protein (HSP) expression and underscore
the role of HSPs in HCV life cycle.
Current HCV treatments are limited and display signiﬁcant side
effect and suboptimal sustained virological response (SVR). For these
reasons, it is necessary to identify/develop additional antiviral thera-
pies that could be used in place of pegylated interferon-a (PEG-IFN)
and ribavirin or as adjunct therapies to increase the SVR. In this study,
we have demonstrated the signiﬁcant antiviral activity of catechin,
quercetin and naringenin. Therefore, these bioﬂavonoids may be
candidates for HCV therapy and may be beneﬁcial for patients unable
to receive PEG-IFN therapy. Furthermore, because of the different
mechanisms of action of these bioﬂavonoids, combining them may
allow for synergistic antiviral activity resulting in better suppression
of HCV.Materials and methods
Bioﬂavonoids
Quercetin (Sigma-Aldrich, 00200595-50MG), catechin (Sigma-
Aldrich, C1251-5G), naringenin (Sigma-Aldrich, N5893-1G), epi-
catechin (Sigma-Aldrich, E4018-5MG), silymarin (Sigma-Aldrich,
R. Khachatoorian et al. / Virology 433 (2012) 346–355354S0292-10G), genistein (Sigma-Aldrich, G6649-5MG), and luteolin
(Sigma-Aldrich, L9283-10MG).
Cell culture
Cell lines Huh-7.5 and 293T were maintained in a humidiﬁed
atmosphere containing 5% CO2 at 37 1C in Dulbecco’s Modiﬁed
Eagle Medium (Mediatech, 10-013-CM) supplemented with 10%
fetal bovine serum (Omega Scientiﬁc, FB-01) and 2 mM L-gluta-
mine (Invitrogen, 25030). 293T cells were purchased from ATCC
(CRL-11268). Huh-7.5 cells were a kind gift from Charles Rice (The
Rockefeller University, New York, NY) (Blight et al., 2002).
Cell viability
Cell viability was determined using MTT Cell Proliferation
assay (ATCC, 30-1010K).
Plasmid constructs
The HCV IRES reporter plasmid and the NS5A and GFP retro-
viral expression vectors pMSCV-NS5A-FLAG and pMSCV-GFP,
respectively, have been previously described (Gonzalez et al.,
2009). An intra-genotype 2 chimeric monocistronic reporter virus,
pNRLFC based on pJ6/JFH-C parental virus has been described
previously (Arumugaswami et al., 2008). For the current study,
we have used a chemically synthesized plasmid pFNX-RLuc
(having similar sequences to pNRLFC) for construction of recom-
binant virus. The pRL-TK (Promega, E2241) plasmid expresses
Renilla luciferase.
Infectious virus production
pFNX-RLuc was in vitro transcribed, and the puriﬁed RNA was
electroporated into huh-7.5 cells to generate infectious viral
supernatant as previously described (Arumugaswami et al., 2008).
Viral assays
All viral assays were done using the HCV reporter virus and
with the same titer and multiplicity of infection as described
previously (Gonzalez et al., 2009; Khachatoorian et al., 2012).
Intracellular viral protein production: Huh-7.5 cells were
infected for 3 h, and cells were harvested at the indicated time
points. Luciferase activity was measured using the Renilla Lucifer-
ase Assay System (Promega, E2820). Infectious virion secretion:
The supernatants from the above cultures were concentrated 30-
fold by using Amicon Ultra-0.5 mL Centrifugal Filters (Millipore,
UFC510096) to remove excess bioﬂavonoids and used to infect
naı¨ve cells for 3 h. Cells were harvested 72 h later, and Renilla
luciferase activity was measured. Intracellular infectious virion
assembly: Huh-7.5 cells were infected for 3 h, and supernatants
were removed at indicated time points. Cells were washed with
PBS, and fresh medium was added. The cultures were subjected to
three cycles of freeze–thaw to release assembled viral particles.
These suspensions were cleared of cellular debris and used to
infect naı¨ve cells for 3 h. Subsequently, cells were harvested 72 h
post infection, and luciferase activity was assayed.
Quantitative reverse-transcriptase PCR
Huh-7.5 cells were infected with the Renilla reporter virus for
3 h. Seventy-two hours post infection, cells were harvested, and
total RNA was extracted using RNeasy Mini Kit (Qiagen, 74104).
cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad,
1708891). Quantitative PCR was performed using the AppliedBiosystems 7500 Fast Real-Time PCR System with 2x SYBR Green
Master Mix (Diagenode, GMO-SG2x-A300) in 25 mL reactions. The
real-time PCR cycling conditions were 50 1C for 2 min and 95 1C
for 10 min, followed by 40 cycles at 95 1C for 15 s, 60 1C for 30 s,
and 72 1C for 30 s each as well as a ﬁnal dissociation stage of 95 1C
for 15 s and 60 1C for 1 min. The primers for the viral genome
were derived from the 50-non-coding region and were
CTGGGTCCTTTCTTGGATAA and CCTATCAGGCAGTACCACA. HCV
RNA levels were normalized to the housekeeping gene actin using
the primers CCAACCGCGAGAAGATGA and CCAGAGGCGTACAG
GGATAG.
IRES reporter assay
293T cells were treated with 125 mM bioﬂavonoids. Two hours
later, cells were transfected with the HCV IRES reporter plasmid
and either pMSCV-NS5A-FLAG or pMSCV-GFP. All transfections
were done using Fugene6 (Roche, 11814443001). Forty-eight
hours post transfection, Renilla and Fireﬂy luciferase activity were
determined using Dual Luciferase Assay System (Promega,
E1910).
Antibodies
NS5A (Abcam, ab20342), HSP70 (Santa Cruz Biotech, C92F3A-5),
and tubulin (abcam, ab6160).
Densitometry
Western blot images were analyzed by ImageJ v1.45s software
according to software instructions.
Statistical analysis
Error bars reﬂect the standard deviation. P values were
determined by student t-test.Acknowledgments
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